MTHFR C677T: What the Evidence Actually Says
rs1801133 is one of the most searched variants in any raw file and one of the most oversold. What the TT genotype does and does not do, and what guidelines say.
If you have searched your own raw data, there is a good chance MTHFR was one of the first things you looked up. It is also the variant most likely to have sent you down a rabbit hole of supplements, “methylation protocols” and alarming lists of conditions. The underlying biology is real and interesting. Most of what is built on top of it is not.
The enzyme and the variant
MTHFR stands for methylenetetrahydrofolate reductase, an enzyme in the folate cycle that helps convert one form of folate into the form the body uses to recycle homocysteine into methionine. The famous variant is C677T, reported in raw files as rs1801133. On the forward strand the common allele is G and the variant allele is A, so the genotype often written as “TT” in the literature appears as AA in your file, and “CT” appears as AG.
Frosst and colleagues described it in 1995: the variant swaps one amino acid (alanine to valine) and makes the enzyme less stable at body temperature. People with two copies have roughly 30 to 40 percent of typical enzyme activity; one copy leaves around 65 to 70 percent.
A second variant, A1298C (rs1801131, forward-strand variant allele G), has a milder effect, and its main relevance is in combination with 677T.
How common it is
This is not a rare mutation. Around 30 to 40 percent of people of European ancestry carry one copy of 677T, and roughly 8 to 15 percent carry two. Frequencies are higher in some Hispanic and East Asian populations and lower in people of African ancestry. Something carried by one in ten people is, by definition, a normal part of human variation rather than a defect.
What two copies actually do
The reproducible finding is modest: TT individuals tend to have somewhat higher blood homocysteine, especially when their folate intake is low. Give them adequate folate and the difference largely disappears. That interaction is the key to reading everything else about MTHFR.
The historical worry was that elevated homocysteine might raise the risk of blood clots and cardiovascular disease. Large studies and trials that lowered homocysteine with B vitamins did not produce the expected drop in heart attacks or strokes, and the association with clotting turned out to be weak to absent. That is why the American College of Medical Genetics issued a practice guideline in 2013 stating that MTHFR testing should not be ordered as part of a thrombophilia work-up - there was no evidence it changed management.
There is one area with a real, if small, signal: neural tube defects. The TT genotype in mothers is associated with a modestly increased risk, and this is one reason folic acid before and during early pregnancy is recommended to everyone. Notably, the CDC’s position is that ordinary folic acid works for people with MTHFR variants; there is no evidence that they need a special form.
The claims that do not hold up
Search results for MTHFR attach it to anxiety, autism, chronic fatigue, migraine, miscarriage, “detox” problems and dozens of other conditions. For most of these there is no consistent evidence at all. For a few - migraine with aura, recurrent pregnancy loss - there are small positive studies alongside larger null ones, which is the usual signature of an association that is either tiny or not real.
Three specific claims deserve direct answers:
- “TT means you cannot process folic acid.” No. Enzyme activity is reduced, not absent. Folic acid raises folate status in TT individuals in every trial that has measured it.
- “You must take methylfolate.” There is no evidence that methylfolate outperforms folic acid for people with 677T at ordinary doses. It is not harmful, but it is not required.
- “MTHFR explains my symptoms.” With a variant this common, any symptom you have will be found in plenty of TT people and plenty of CC people. Coincidence is the default explanation until a study shows otherwise.
Reading it sensibly
If you find AA at rs1801133 in your file, the reasonable takeaways are ordinary ones: eat folate-rich food, take standard folic acid if pregnancy is possible, and mention it to a doctor only if they are already investigating homocysteine for some other reason. Nobody needs a treatment plan for a genotype that a tenth of the population shares.
MTHFR is a good case study in how a single, real biochemical finding gets inflated as it travels. The same pattern shows up with the “warrior gene” COMT and with polygenic traits pinned to one SNP; our guide to polygenic scores explains why single-variant stories so often disappoint.
References
- Frosst P, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genetics. 1995. PubMed 7647779
- Hickey SE, Curry CJ, Toriello HV. ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing. Genetics in Medicine. 2013. PubMed 23288205
- Centers for Disease Control and Prevention. MTHFR Gene Variant and Folic Acid Facts.
- dbSNP entries for rs1801133 and rs1801131, NCBI.
This article is educational only and is not medical advice. Decisions about supplements in pregnancy or for a diagnosed condition belong with your doctor.